Mark A. Meeker, DO, FACP, CPE

Panelists discuss the key considerations for properly coding chronic kidney disease (CKD) diagnoses, with a particular focus on the nuances involved in coding for early-stage CKD.

Panelists discuss how NCQA guidelines apply to chronic kidney disease (CKD) management and the role of the KDIGO heat map in enhancing clinical practice.

Panelists discuss how multidisciplinary teams can enhance holistic patient care in managing chronic kidney disease (CKD) and its associated risks, emphasizing the importance of ongoing education and collaboration across disciplines, along with established protocols for screening and testing in health systems and the challenges faced in their implementation for patients with type 2 diabetes at risk for or currently diagnosed with CKD.

Panelists discuss the common barriers to implementing new chronic kidney disease (CKD) treatments and guidelines in clinical practice, as well as the role of pharmaceutical partners in overcoming these challenges to enhance CKD treatment adoption.

Panelists discuss the role of cardiovascular risk management for patients with chronic kidney disease (CKD) and how cardiovascular care can be effectively integrated into CKD management strategies.

Panelists discuss the treatment options available for patients with early-stage versus advanced chronic kidney disease (CKD) and how these options should be tailored to individual patient conditions, as well as the mechanism of action of nonsteroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone and their comparison to other treatment modalities.

Panelists discuss the treatment of a patient with type 2 diabetes who develops a genital mycotic infection while on an SGLT-2 inhibitor, weighing the options of treating with topical antifungals versus discontinuing the medication, as well as addressing concerns for a patient on a GLP-1 receptor agonist and RAAS inhibitor who is experiencing adverse effects such as bloating and nausea while considering the benefits of continuing therapy.

Panelists discuss how SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists differ in their treatment of chronic kidney disease (CKD) in patients with type 2 diabetes, along with strategies for managing hyperkalemia in patients to help them resume their treatment course.

Panelists discuss the high rates of missed chronic kidney disease (CKD) diagnoses despite testing and the consequences of diagnosing CKD in patients with type 2 diabetes without administering treatment, including insights on how frequently this occurs among cardiologists and primary care providers.

Panelists discuss how early detection of chronic kidney disease (CKD) in stages 2 and 3 can improve patient outcomes across various specialties, including nephrology, cardiology, and primary care.

Panelists discuss the current barriers to urine albumin-creatinine ratio (uACR) testing, strategies to address these barriers, the guideline goals for reducing uACR, and the importance of a multimodal approach, as well as how increased awareness of chronic kidney disease (CKD) testing can improve patient outcomes and engage health care providers in promoting testing.

Panelists discuss key updates in clinical guidelines for chronic kidney disease (CKD) testing in patients with type 2 diabetes, highlighting the latest recommendations for improving screening and diagnosis.

Panelists discuss the criteria for identifying at-risk patients for chronic kidney disease (CKD) testing in type 2 diabetes and review the screening and detection tests, emphasizing the critical importance of early detection through blood and urine tests for both CKD management and heart failure prevention.

Panelists discuss the prevalence of chronic kidney disease (CKD) in patients with type 2 diabetes and how CKD significantly impacts overall patient health.